Ostatné · NTLA
Intellia Therapeutics, Inc.
Fundamenty firmy Healthcare · Biotechnology · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 17 hodnotení
nákup
- Najnižší cieľ
- 8,00
- Priemerný cieľ
- 24,00
- Najvyšší cieľ
- 61,00
- Potenciál
- +94,0 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | -0,79 | -0,89–-0,71 | -0,92 | +14,3 % |
| budúci štvrťrok | -0,76 | -0,91–-0,41 | -0,83 | +8,4 % |
| tento rok | -3,16 | -3,41–-2,83 | -3,81 | +17,2 % |
| budúci rok | -2,60 | -3,62–0,97 | -3,16 | +17,7 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 9,8 mil. | 13,8 mil. | −29,1 % |
| budúci štvrťrok | 17,1 mil. | 23,0 mil. | −25,8 % |
| tento rok | 51,9 mil. | 67,7 mil. | −23,3 % |
| budúci rok | 126,3 mil. | 51,9 mil. | +143,4 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Leonard John MChief Executive Officer | predaj | 286 819 | 21.08. |
| Dulac Edward J IiiChief Financial Officer | predaj | 91 249 | 22.07. |
| Dulac Edward J IiiChief Financial Officer | predaj | 84 186 | 02.07. |
| Dube Michael POfficer | predaj | 44 316 | 01.07. |
| Cohen Frederick E. M.d. Ph.d.Director | odmena v akciách | – | 09.06. |
| Verwiel FrankDirector | odmena v akciách | – | 09.06. |
| Chase William JDirector | odmena v akciách | – | 09.06. |
| Goodman JesseDirector | odmena v akciách | – | 09.06. |
| Keresty GeorgiaDirector | odmena v akciách | – | 09.06. |
| Bhanji MunaDirector | odmena v akciách | – | 09.06. |
| Goff Brian MDirector | odmena v akciách | – | 09.06. |
| Basta James EdmundGeneral Counsel | predaj | 16 688 | 02.03. |
Kto vlastní akcie
Slávni investori: Cathie Wood · 1.9 %
ARK Investment Management, LLC12,04 %
Blackrock Inc.11,00 %
State Street Corporation6,59 %
Vanguard Portfolio Management LLC5,23 %
Shaw D.E. & Co., Inc.4,60 %
Vanguard Capital Management LLC4,30 %
Two Sigma Investments, LP3,74 %
FMR, LLC3,41 %
O firme (popis z Yahoo Finance, anglicky)
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou NTLA.